title: rh-BMP2-induced ectopic bone for grafting critical size defects: a preliminary histological evaluation in rat calvariae.
abstract: The aim of this study was to evaluate histologically the biological usefulness of recombinant human BMP2 (rh-BMP2)-induced ectopically-formed bone as graft material to repair a bone defect model, compared with autogenous bone and frozen allogeneic bone. Forty-five male Wistar rats were used, which were divided into three graft groups. Each of the three graft groups was divided into three observation period groups (3, 6 and 9 weeks after graft). All rats underwent craniotomy to create a bone defect, and then received a bone graft. In the rh-BMP2-induced ectopic bone graft group, marked bone formation was seen from 3 weeks after graft. In the autogenous bone graft group, marked bone formation was seen from 6 weeks after graft. In the group that received a frozen allogeneic bone graft, marked bone formation was seen from 9 weeks after graft. At 3, 6 and 9 weeks after graft, newly formed bone area was significantly greater in the tissue engineered bone (TEB) group than in the auto or frozen allogeneic bone (FAB) group. rh-BMP2-induced ectopically-formed bone graft exhibited better osteoconductivity than autogenous bone graft and frozen allogeneic bone graft. These histological findings indicate that rh-BMP2-induced ectopically-formed bone is suitable as bone graft material.
authors.affiliation: Department of Oral and Maxillofacial Surgery, Shiga University of Medical Science, Setatsukinowacho Otsu, Shiga, Japan. inoda@belle.shiga-med.ac.jp
authors.forename: H
authors.initials: H
authors.lastname: Inoda
authors.forename: G
authors.initials: G
authors.lastname: Yamamoto
authors.forename: T
authors.initials: T
authors.lastname: Hattori
mesh_terms: D020341:Absorbable Implants; D000818:Animals; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000494:pharmacology*; D016025:Bone Transplantation / Q000379:methods*; D020219:Chondrogenesis; D003094:Collagen / Q000187:drug effects*; D004337:Drug Carriers; D006801:Humans; D020007:Implants, Experimental; D008297:Male; D010012:Osteogenesis; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000494:pharmacology; D017568:Rectus Abdominis; D012886:Skull / Q000601:surgery; D023822:Tissue Engineering / Q000379:methods*; D016212:Transforming Growth Factor beta / Q000494:pharmacology*
chemical_list: C525718:BMP2 protein, human; C525720:Bmp2 protein, rat; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D004337:Drug Carriers; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C059821:atelocollagen; D003094:Collagen